Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

NICE backs Takeda’s Alunbrig in second-line lung cancer

pharmaceutical-technologyFebruary 20, 2019

Tag: NICE , Takeda , ALK , Alunbrig

PharmaSources Customer Service